sodium oxybate ER

targets

all catalysts(0)

nothing on the calendar yet

News(8)

• With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
  Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of…
  fiercebiotech · 15d ago
• ‘A neuroscience revolution’: The GLP-like race to keep us awake and make billions doing it
  As the hype around the vast medical potential of GLP-1 drugs continues unabated, another peptide is starting to make its own mark.
  fiercebiotech · 1mo ago
• Takeda leads wave of orexin drugs with potential to upend narcolepsy market
  The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
  biospace · 1mo ago
• Takeda’s narcolepsy nod opens orexin doors
  Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for t…
  biospace · 1mo ago
• STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
  The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions.
  stat · 1mo ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 1mo ago
• Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
  Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
  biopharma_dive · 3mo ago
• Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
  Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
  endpoints · 4mo ago